Developer · China
CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
A Shijiazhuang-based pharmaceutical R&D and manufacturing subsidiary of CSPC Pharmaceutical Group, developing and sponsoring CNS and other small-molecule programs including the SNRI antidepressant ammoxetine.
1compound
1program
1indication
Phase 3lead asset
Pipeline (1)
- Major depressive disorderPhase 3Active
Catalysts · 1 upcoming · 1 reported
- 1H 2026Anticipated
Ammoxetine (S-071031B)forMajor depressive disorderTopline data
Sertraline-controlled Phase 3 MDD topline anticipated; primary-completion estimate 30 Jun 2026.
Recently reported
- 2025-09-01met
Ammoxetine (S-071031B)forMajor depressive disorderFull results
Phase 2 MDD trial positive: ammoxetine 40 and 60 mg/day beat placebo on MADRS at Week 8.
Recent activity
- Sep 1, 2025ReadoutAmmoxetine (S-071031B)·Major depressive disordermetPhase 2 MDD trial positive: ammoxetine 40 and 60 mg/day beat placebo on MADRS at Week 8.source ↗
- Feb 14, 2025Phase changeAmmoxetine (S-071031B)·Major depressive disorderPhase 3Phase 3 sertraline-controlled study (NCT06827431) registered with an estimated start date of 14 Feb 2025; registry overall status NOT_YET_RECRUITING at research time. Phase advanced to Phase 3 in MDD.source ↗
- Oct 15, 2024Phase changeAmmoxetine (S-071031B)·Major depressive disorderPhase 2Phase 2 MDD study (NCT05762458, n=239, 15 China sites) completed; primary MADRS endpoint met for both 40 mg/day and 60 mg/day vs placebo at Week 8. Estimated study completion 15 Oct 2024; results published in JAMA Network Open September 2025.source ↗
Competitive landscape
Other companies developing against CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.'s targets or indications.
- Alto Neuroscience, Inc.2 compoundsMajor depressive disorder
- Autobahn Therapeutics, Inc.1 compoundMajor depressive disorder
- Axsome Therapeutics, Inc.1 compoundMajor depressive disorder
- Beckley Psytech Limited1 compoundMajor depressive disorder
- Biohaven Ltd.1 compoundMajor depressive disorder
- Boehringer Ingelheim International GmbH2 compoundsMajor depressive disorder
- Cerevel Therapeutics Holdings, Inc.1 compoundMajor depressive disorder
- COMPASS Pathways plc1 compoundMajor depressive disorder
- Definium Therapeutics, Inc.1 compoundMajor depressive disorder
- Delix Therapeutics, Inc.1 compoundMajor depressive disorder
- Draig Therapeutics Ltd1 compoundMajor depressive disorder
- Engrail Therapeutics, Inc.1 compoundMajor depressive disorder